4th Feb 2009 07:00
Sinclair Pharma plc Sinclair strengthens its European sales and marketing operations and further expands its export network with 19 new agreements
4th February 2009, Godalming, UK: Sinclair Pharma plc ("Sinclair": SPH:L), the international specialty pharma company, today announces it has strengthened its sales and marketing operation in Spain, by acquiring the remaining shares of Laboratorios Novo Pharma S.L. and creating a new fully owned Sinclair operating company, Sinclair Pharma Espana.
Previously Sinclair held 50.05% of the shares and it has now purchased the outstanding 49.95% owned by Laboratorios Novo Pharma S.L. management for € 330,000. This transaction has been funded by a specific facility arranged with one of our current bankers. As a result Sinclair now has 100% owned operations in France, Italy, UK and Spain.
Sinclair has also appointed Santiago Calavia Torres as Operations Manager of Dermatology of Sinclair Pharma Espana. Santiago qualified as a biochemist and has held senior sales and marketing positions in Pharmacia & Upjohn and for the past ten years has been Director of Business Development of Southern Europe & New Products at Daiichi Sankyo, Inc.
Sinclair also announced today the appointment of Paolo Prioglio as Sales & Marketing Director of Sinclair Srl in Italy. Prior to joining Sinclair, Paolo worked in senior sales and marketing and general management roles for a number of dermatology companies, including Pierre Fabre.
Operational Progress:
Since the update provided in the Interim Management Statement in November 2008 Sinclair has continued to see a roll-out of its products in new markets and growth of its international sales network through new marketing agreements.
Product News:
* 19 new distribution agreements have been signed covering 15 products in 11
countries.
This brings the total number of new deals in this financial year to 39 in aggregate representing minimum purchase obligations of €3.5 million under these new agreements in the first year after product launch.
* Five product launches were achieved in three countries : * + Sebclair Shampoo & Scalp Fluid in Italy for the management of seborrhoeic dermatitis of the scalp + Gen-Ongles in Italy for nail care + Aloclair Gel in Argentina for mouth ulcers + Sebclair cream in Spain
Regulatory & Clinical News:
* Registrations were approved in the EU for Decapinol Perio vials for the management of gum pockets in periodontal disease and Dermachronic foam. * 3 new publications were achieved * Atopiclair Cream: Treatment of pruritus in mild to moderate atopic dermatitis with a topical non steroidal agent. Veraldi S, Lunardon L, Schianchi R; The Journal of Drugs in Dermatology. (Accepted January 2009) and two studies evaluating the emollient Dermachronic cream and cleanser and our acne product Papulex cream oil free.
Dr Michael Flynn, CEO of Sinclair Pharma commented:
"We have worked closely with Laboratorios Novo Pharma S.L. over recent years to establish the joint operation, and now look forward to developing this further. This acquisition is an important step in further strengthening of our sales and marketing presence in the major European countries."
"We anticipate continued steady sales growth with the launch of further products from both our own operations and marketing partners, and the addition of 19 newagreements since late November, bringing the total number of new agreements so far this financial year to 39."
"We continue to generate scientific data to support the sales of our products, reflected in three further papers recently accepted for publication."
-ends -
For further information please contact:
Sinclair Pharma plc Tel: +44 (0) 1483 410 600
Dr Michael Flynn, CEO
Jerry Randall, CFO
Mariyam Rawat, Communications & Investor relations [email protected]
Capital MS&L
Mary Clark, Anna Mitchell Tel +44 (0)20 7307 5340
Notes to Editors:
About Sinclair Pharma Plc www.sinclairpharma.com
Sinclair Pharma plc is an international specialty pharmaceutical company. It has a growing sales and marketing operation that is already present in France, Italy, UK, Spain and Portugal, and a complementary marketing partner network that spans more than 80 countries.
Sinclair has proven expertise in acquiring or developing commercially attractive and undervalued products, registering these products and bringing them to market within a short timeframe. Sinclair focuses on niche therapeutic areas and its current portfolio includes products for dermatological conditions and oral health.
Product Information:
Sinlice: This product is designed to meet a market need for a novel, safe and effective treatment for head lice. The OTC market for the five main EU territories and the US is worth an estimated £120m. Sinlice uses proprietary barrier technology to coat and suffocate head lice and their eggs, killing them and making them easy to remove. Sinclair applied its expertise in topical and barrier formulations to develop Sinlice, entering a new therapeutic area for the company. The product can be sold without a prescription in the EU since its registration as a medical device in December 2007.
Herpclair: This is a proprietary topical treatment aimed at rapidly reducing the symptoms of herpes simplex cold sores and accelerating the healing process. The product is registered as Medical Device Class IIa and can be sold without a prescription in the EU. The OTC market for herpes simplex products in the UK, France and Germany is valued at £83m. In Spain and Italy, products for cold sores are commonly prescribed, opening up a new sector of the market for Sinclair in these regions. Herpclair is an important addition to the company's product range and its commercialisation will contribute to our growing presence in the EU market. Herpclair was registered in the EU as a medical device in January 2008.
Decapinol Perio-Applicator and Perio-vialsarepart of the "Decapinol Suite", an innovative system that includes two different options for treating local periodontal pockets. The first step is professional intervention with Decapinol Perio, composed of a unique ergonomically designed applicator that is used with Perio-Vials which contain delmopinol hcl solution. The second step is follow-up home care with Decapinol gel. These two formulations can be used along the margins of the sub and supra-gingival and into interdental spaces. Decapinol suite's key ingredient is delmopinol hcl; delmopinol hcl has a novel mechanism of action, which is to reduce the adherence of bacterial plaque to the teeth and gingiva, and also to other plaque. Decapinol gel also contains additional ingredients to improve overall gum health and to help relieve pain followed by treatment.
Dermachronic: DermaChronic is an emollient non-allergenic moisturiser, developed specifically for long term use in remission by patients with chronic skin conditions. This new product is available as a cream and a detergent line extension.
Papulex: is a line of cosmetic products specifically targeted at cleansing, protecting and keeping acne prone skin in good condition. It can be used alone or in combination with conventional acne therapy.
Aloclair: incorporates `coating' technology to provide fast and effective pain relief from the discomfort of mouth ulcers and other minor oral lesions. When sprayed onto the ulcer, a barrier is formed that protects the ulcer from painful stimulation by chewing, speaking, food or drink.
Sebclair is indicated to manage and relieve the itching, burning, scaling and pain experienced with seborrhoeic dermatitis. It is a non-steroidal, barrier enhancing, mildly keratolytc composition of ingredients formulated to help normalize skin physiology altered by seborrhoeic dermatitis and cradle cap in infants.
Bio-Taches line of products helps reduce sun induced brown spots and brown aging spots, and at the same time helps to make the skin to look younger and fresher, and support skin after dermatological treatments such as peeling.
Affina Lift prevents and corrects the effect of skin aging thanks to Lipofine, an
essential ingredient able to strengthen and restructure the supporting fibres of
the face, chin and neck.
Effadiane is a line of products is designed to help relieve skin dryness caused by sun, wind, allergies or sensitivities.
B•derm is a comprehensive hyaluronic acid based line for sensitive and hyperreactive skin.
B•lift line, a group of unique anti-wrinkle products containing Hexapeptide B, the botulin-like molecule for a Botox-like lifting tensor effect.
Optys : Targeted and complete products for treatment and prevention of the typical
problems of the eye contour area such s dark circles
Keren 2 is part of the Kerexil range, containing a formula able to act both on decreased bulb tonicity of the hair shaft and deficiency in nutritional factors.
Gen-ongles is indicated for nail deficiencies, onychoschizia, onychorrhexis, and as adjuvant in anti-fungal treatments. It acts both inside the nail thanks to silicon and outside thanks to the filmogen action.
"Safe Harbor" Statement under the US Private Securities Litigation Reform Act of 1995: Some or all of the statements in this document that relate to future plans, expectations, events, performances and the like are forward-looking statements, as defined in the US Private Securities Litigation Reform Act of 1995. Actual results of events could differ materially from those described in the forward-looking statements due to a variety of factors.
vendorRelated Shares:
Sinclair Pharma